BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 19093708)

  • 1. Teriparatide: a review of its use in osteoporosis.
    Blick SK; Dhillon S; Keam SJ
    Drugs; 2008; 68(18):2709-37. PubMed ID: 19093708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on teriparatide in osteoporosis.
    Blick SK; Dhillon S; Keam SJ
    BioDrugs; 2009; 23(3):197-9. PubMed ID: 19627171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in bone quality and strength with bone-forming agents].
    Miyakoshi N
    Clin Calcium; 2016 Jan; 26(1):117-24. PubMed ID: 26728538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriparatide: A bone formation treatment for osteoporosis.
    Eriksen EF; Robins DA
    Drugs Today (Barc); 2004 Nov; 40(11):935-48. PubMed ID: 15645006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
    Dobnig H
    Expert Opin Pharmacother; 2004 May; 5(5):1153-62. PubMed ID: 15155114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
    Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B
    Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?
    Girotra M; Rubin MR; Bilezikian JP
    Treat Endocrinol; 2006; 5(6):347-58. PubMed ID: 17107220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indications to teriparatide treatment in patients with osteoporosis.
    Rizzoli R; Kraenzlin M; Krieg MA; Mellinghoff HU; Lamy O; Lippuner K
    Swiss Med Wkly; 2011; 141():w13297. PubMed ID: 22057669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriparatide: a review.
    Quattrocchi E; Kourlas H
    Clin Ther; 2004 Jun; 26(6):841-54. PubMed ID: 15262455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.
    Cosman F; Nieves JW; Dempster DW
    J Bone Miner Res; 2017 Feb; 32(2):198-202. PubMed ID: 27925287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis.
    Augustine M; Horwitz MJ
    Curr Osteoporos Rep; 2013 Dec; 11(4):400-6. PubMed ID: 24078470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2012 Mar; 22(3):315-20. PubMed ID: 22370297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.